Many neurodegenerative diseases are characterized by the conformational change of self-proteins into amyloidogenic, pathological conformers, which share structural properties such as high ?-sheet content and resistance to degradation. Alzheimer's disease (AD) is the most common of the neurodegenerative protein conformational disorders, which include diffuse Lewy body disease (DLBD), Parkinson's disease (PD), prion diseases, and frontotemporal lobar degeneration (FTLD). The most toxic conformers are the oligomeric forms. None of the conformational diseases has an effective therapy;however, immunomodulation has shown great promise for both AD and prion diseases. Major problems with this approach include: the potential of toxicity from encephalitis (related to excessive cell mediated immunity), the immunological targeting of both the normal and abnormal A?, the resistance of vascular amyloid to clearance, as well as tau related pathology not being specifically addressed. The central hypothesis of this proposal is that each of these limitations can be overcome by specific targeting of abnormal oligomer conformation and development of novel methods to prevent oligomer mediated toxicity. Our novel active immunomodulation approach uses a polymerized British amyloidosis (pABri) related peptide in a predominantly ?-sheet, oligomeric form. We hypothesized that through "conformational mimicry" the polymerized ABri peptide could induce a conformation selective immune response that will recognize both A? and conformationally abnormal tau. This hypothesis is supported by preliminary data in an APP/PS1 AD mouse model. Such an immunostimulatory approach should have a reduced risk of inducing auto-immune complications as it is more specific to a pathological conformer and the immunogen has no sequence homology to any known mammalian protein/peptide. We also present preliminary data that short term treatment with monoclonal 6D11, an anti-PrP antibody, reverses behavioral deficits in an AD model APP/PS1 Tg mice. This antibody blocks the binding of A? oligomers to PrPC. We hypothesize that blocking the binding of A? oligomers and PrPC is a novel therapeutic strategy for AD. These complementary approaches will aim to both increase clearance of A? oligomers and specifically block their toxicity.

Public Health Relevance

Many neurodegenerative diseases are characterized by the conformational change of self-proteins into amyloidogenic, pathological conformers, which share structural properties such as high ?-sheet content and resistance to degradation. Alzheimer's disease (AD) is the most common of the neurodegenerative protein conformational disorders, which include diffuse Lewy body disease (DLBD), Parkinson's disease (PD), prion diseases, and frontotemporal lobar degeneration (FTLD). The most toxic conformers are the oligomeric forms, which we plan to target by developing novel approaches to both increase their clearance and to reduce their toxicity.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS073502-03
Application #
8282910
Study Section
Special Emphasis Panel (ZRG1-BDCN-Y (02))
Program Officer
Corriveau, Roderick A
Project Start
2010-09-01
Project End
2015-06-30
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
3
Fiscal Year
2012
Total Cost
$362,294
Indirect Cost
$147,919
Name
New York University
Department
Neurology
Type
Schools of Medicine
DUNS #
121911077
City
New York
State
NY
Country
United States
Zip Code
10016
Goñi, Fernando; Mathiason, Candace K; Yim, Lucia et al. (2015) Mucosal immunization with an attenuated Salmonella vaccine partially protects white-tailed deer from chronic wasting disease. Vaccine 33:726-33
Sabharwal, Priyanka; Wisniewski, Thomas (2014) Novel immunological approaches for the treatment of Alzheimer's disease. Zhongguo Xian Dai Shen Jing Ji Bing Za Zhi 14:139-151
Zhang, Ying; Shi, Zhihong; Liu, Mengyuan et al. (2014) Prevalence of cognitive impairment no dementia in a rural area of Northern China. Neuroepidemiology 42:197-203
Iulita, M Florencia; Do Carmo, Sonia; Ower, Alison K et al. (2014) Nerve growth factor metabolic dysfunction in Down's syndrome brains. Brain 137:860-72
Scholtzova, Henrieta; Chianchiano, Peter; Pan, Jason et al. (2014) Amyloid ? and Tau Alzheimer's disease related pathology is reduced by Toll-like receptor 9 stimulation. Acta Neuropathol Commun 2:101
Wisniewski, Thomas; Goñi, Fernando (2014) Immunotherapy for Alzheimer's disease. Biochem Pharmacol 88:499-507
Boutajangout, Allal; Wisniewski, Thomas (2014) Tau-based therapeutic approaches for Alzheimer's disease - a mini-review. Gerontology 60:381-5
Liu, Shan; Breitbart, Ariel; Sun, Yanjie et al. (2014) Blocking the apolipoprotein E/amyloid * interaction in triple transgenic mice ameliorates Alzheimer's disease related amyloid * and tau pathology. J Neurochem 128:577-91
Wegiel, Jerzy; Flory, Michael; Kuchna, Izabela et al. (2014) Brain-region-specific alterations of the trajectories of neuronal volume growth throughout the lifespan in autism. Acta Neuropathol Commun 2:28
Goni, Fernando; Herline, Krystal; Peyser, Daniel et al. (2013) Immunomodulation targeting of both A* and tau pathological conformers ameliorates Alzheimer's disease pathology in TgSwDI and 3xTg mouse models. J Neuroinflammation 10:150

Showing the most recent 10 out of 19 publications